Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2215/CJN.01600214 http://scihub22266oqcxt.onion/10.2215/CJN.01600214 C4152805!4152805 !24832093     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24832093 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Clin+J+Am+Soc+Nephrol 2014 ; 9 (9 ): 1657-67 Nephropedia Template TP {{tp|p=24832093 |t=2014. Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis |pdf=|usr=}}{{24832093 }} gab.com Text Is newer safer Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis JO: Clin J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=24832093 #FOAvip Clinical outcomes in ANCA-associated vasculitis (AAV) and lupus nephritis have improved greatly with treatment regimens containing high-dose glucocorticoids and cyclophosphamide. However, with the use of these medications come significant adverse events, most notably infections, cytopenias, malignancies, and reproductive abnormalities. Multiple recent randomized controlled trials in AAV and lupus nephritis have compared cyclophosphamide-based regimens with agents such as rituximab, mycophenolate mofetil, and azathioprine, with the hope of providing better clinical outcomes with improved safety profiles. Although some of these newer regimens are now considered first-line treatments of these diseases, their adverse event profiles have been disappointingly similar to those of cyclophosphamide-based protocols. Physicians and patients should consider the adverse event profiles generated by these trials in the context of their extensive use in other patient populations, as well as available measures to prevent such events, when choosing the ideal regimen for an individual patient. Twit Text FOAVip Is newer safer Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis ????Clin J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=24832093 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24832093 #FOAvip English Wikipedia <ref>{{Cite pmid|24832093 }}</ref> Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis #MMPMID24832093 Hogan J ; Avasare R ; Radhakrishnan J Clin J Am Soc Nephrol 2014[Sep]; 9 (9 ): 1657-67 PMID24832093 show ga Clinical outcomes in ANCA-associated vasculitis (AAV) and lupus nephritis have improved greatly with treatment regimens containing high-dose glucocorticoids and cyclophosphamide. However, with the use of these medications come significant adverse events, most notably infections, cytopenias, malignancies, and reproductive abnormalities. Multiple recent randomized controlled trials in AAV and lupus nephritis have compared cyclophosphamide-based regimens with agents such as rituximab, mycophenolate mofetil, and azathioprine, with the hope of providing better clinical outcomes with improved safety profiles. Although some of these newer regimens are now considered first-line treatments of these diseases, their adverse event profiles have been disappointingly similar to those of cyclophosphamide-based protocols. Physicians and patients should consider the adverse event profiles generated by these trials in the context of their extensive use in other patient populations, as well as available measures to prevent such events, when choosing the ideal regimen for an individual patient. |Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug therapy [MESH] |Antibodies, Monoclonal, Murine-Derived/adverse effects [MESH] |Cyclophosphamide/adverse effects [MESH] |Humans [MESH] |Immunologic Factors/adverse effects [MESH] |Immunosuppressive Agents/adverse effects [MESH] |Lupus Nephritis/*drug therapy [MESH] |Mycophenolic Acid/adverse effects/analogs & derivatives [MESH] |Randomized Controlled Trials as Topic [MESH]Is newer safer? Adverse events associated with first-line therapies fo(epmc).pdf DeepDyve Pubget Overpricing